Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 14

ESCI
Impact Factor

ISSN: 1179-9889


       

Archive: Volume 14, 2024

Review

The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review

Almodovar Diaz AA, Alouch SS, Chawla Y, Gonsalves WI

Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:71-87

Published Date: 6 December 2024

Original Research

Highly Curative Treatment of High-Risk Acute Promyelocytic Leukemia: Induction and Consolidation with ATRA+ATO+anthracyclines and Maintenance with ATRA+RIF

Liu D, Tong J, Chen E, Wang L, Xue L, Zhang X, Zhao N, Hu X, Zheng C

Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:63-69

Published Date: 29 July 2024

Original Research

Albumin-to-Globulin Ratio Combined with Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor in Multiple Myeloma with Renal Impairment

Zhang Y, Yao X, Zhang Y, Chen Z, Qin Z, Cai Y, Xia W, Hu H

Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:49-62

Published Date: 2 July 2024

Original Research

Identification of a Prognostic Model Based on NK Cell-Related Genes in Multiple Myeloma Using Single-Cell and Transcriptomic Data Analysis

Mei N, Gong S, Wang L, Wang L, Wang J, Li J, Bao Y, Zhang H, Wang H

Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:31-48

Published Date: 4 June 2024

Original Research

AC024896.1/miR-363-3p Axis Regulates the Malignant Progression of Acute Myeloid Leukemia by Cuproptosis-Related Gene MYO1B

Zhang J, Zheng Y, Liu H, Liu B

Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:17-30

Published Date: 24 March 2024

Review

Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies

Malfona F, Testi AM, Chiaretti S, Moleti ML

Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:1-15

Published Date: 13 March 2024